Venus Remedies Ltd (VENUSREM) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 568580, "name": "Venus Remedies", "stock_name": "Venus Remedies", "full_name": "Venus Remedies Ltd", "name_url": "stocks-analysis/venus-remedies", "exchange": 0, "exchangecode": "", "country_id": 34, "currency": "INR", "cmp": "738.85", "chg": -22.65, "chgp": "-2.97%", "dir": -1, "prev_price": "761.50", "mcapval": "968.00 Cr", "mcap": "Micro Cap", "scripcode": 526953, "symbol": "VENUSREM", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE411B01019", "curr_date": "Feb 06", "curr_time": "", "bse_nse_vol": "29.99 k", "exc_status": "Active", "traded_date": "Feb 06, 2026", "traded_date_str": "2026 02 06", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/venus-remedies-568580-0&utm_source=Spage_Header_Score", "mojoone": { "text": "Part of MojoOne Strategy", "type": "MN", "url": "https://www.marketsmojo.com/mojopro/strategy/2", "ismore": 0, "all_data": [], "is_blur": 1, "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/venus-remedies-568580-0&utm_source=Spage_Score_PartofStrategies" } }, "news": { "results": [ { "title": "Venus Remedies Ltd Falls 9.69%: 5 Key Factors Driving the Weekly Decline", "link": "https://www.marketsmojo.com/news/stocks-in-action/venus-remedies-ltd-falls-969-5-key-factors-driving-the-weekly-decline-3826568", "imagepath": "", "date": "2026-02-07 17:00:06", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>2 Feb:</strong> New 52-week and all-time high at Rs.872.8</p>\n <p><strong>3 Feb:</strong> Stock hits upper circuit, closes at Rs.799.00 (+1.51%)</p>\n <p><strong>6 Feb:</strong> Technical momentum shifts amid mixed indicator signals</p>\n <p><strong>Week Close:</strong> Rs.738.90 (-9.69%) vs Sensex +1.51%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.818.15</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.738.90</div><div clas..." }, { "title": "Venus Remedies Ltd Technical Momentum Shifts Amid Mixed Indicator Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/venus-remedies-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-3823590", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VenusRemediesLt_technicaldot_3823590.png", "date": "2026-02-06 08:01:30", "description": "Venus Remedies Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish trend. Despite a slight dip in daily price, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, and moving averages that warrant close attention from investors and market analysts alike." }, { "title": "Venus Remedies Ltd Hits Upper Circuit Amid Strong Buying Pressure", "link": "https://www.marketsmojo.com/news/stocks-in-action/venus-remedies-ltd-hits-upper-circuit-amid-strong-buying-pressure-3818158", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VenusRemediesLt_stocks_hitting_upper_circuit_3818158.png", "date": "2026-02-03 10:05:38", "description": "Venus Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 3 Feb 2026, propelled by robust buying interest and a notable intraday price rally. The stock closed at ₹799.0, marking a maximum daily gain of 5%, underscoring renewed investor confidence despite a recent period of consolidation." }, { "title": "Venus Remedies Ltd Hits New 52-Week High at Rs.872.8", "link": "https://www.marketsmojo.com/news/stocks-in-action/venus-remedies-ltd-hits-new-52-week-high-at-rs8728-3815970", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VenusRemediesLt_priceRelatedfactors_3815970.png", "date": "2026-02-02 09:48:58", "description": "Venus Remedies Ltd has reached a significant milestone by hitting a new 52-week and all-time high of Rs.872.8, marking a remarkable surge in its stock price amid strong market momentum and robust financial performance." }, { "title": "Venus Remedies Ltd Stock Hits Record High of Rs.872.8 on 2 Feb 2026", "link": "https://www.marketsmojo.com/news/stocks-in-action/venus-remedies-ltd-stock-hits-record-high-of-rs8728-on-2-feb-2026-3815918", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VenusRemediesLt_priceRelatedfactors_3815918.png", "date": "2026-02-02 09:33:32", "description": "Venus Remedies Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a new all-time high of Rs.872.8 on 2 Feb 2026, underscoring its robust performance and sustained growth trajectory in a competitive market environment." }, { "title": "Venus Remedies Ltd Downgraded to Buy Amid Valuation and Technical Shifts", "link": "https://www.marketsmojo.com/news/stock-recommendation/venus-remedies-ltd-downgraded-to-buy-amid-valuation-and-technical-shifts-3815784", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VenusRemediesLt_mojoScore_3815784.png", "date": "2026-02-02 08:36:53", "description": "Venus Remedies Ltd has seen its investment rating downgraded from Strong Buy to Buy as of 1 February 2026, reflecting a recalibration of its valuation and technical outlook despite robust financial performance and quality metrics. The revised Mojo Score now stands at 74.0, signalling a solid but more cautious stance on the stock within the Pharmaceuticals & Biotechnology sector." }, { "title": "Venus Remedies Ltd Valuation Shifts Signal Changing Market Sentiment", "link": "https://www.marketsmojo.com/news/stocks-in-action/venus-remedies-ltd-valuation-shifts-signal-changing-market-sentiment-3813655", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VenusRemediesLt_valuationdot_3813655.png", "date": "2026-02-01 08:02:56", "description": "Venus Remedies Ltd has recently experienced a notable shift in its valuation parameters, moving from a very attractive to a fair valuation grade. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, invites a closer examination of the company’s price attractiveness relative to its historical performance and peer group within the Pharmaceuticals & Biotechnology sector." }, { "title": "Venus Remedies Ltd Gains 12.63%: 4 Key Factors Driving the Surge", "link": "https://www.marketsmojo.com/news/stocks-in-action/venus-remedies-ltd-gains-1263-4-key-factors-driving-the-surge-3813113", "imagepath": "", "date": "2026-01-31 17:01:22", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>27 Jan:</strong> Stock opens strong at Rs.750.20 (+3.28%)</p>\n <p><strong>29 Jan:</strong> Q3 FY26 results reveal profit surge; upgraded to Strong Buy; bullish technical momentum</p>\n <p><strong>30 Jan:</strong> Hits upper circuit at Rs.818.00 (+4.67%) on robust buying</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.726.40</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.818.15</div><div class=\"stat-change positive\">+12.63%</div></div>\n ..." }, { "title": "Are Venus Remedies Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-venus-remedies-ltd-latest-results-good-or-bad-3811909", "imagepath": "", "date": "2026-01-30 19:24:15", "description": "Venus Remedies Ltd's latest financial results reveal a complex operational landscape characterized by notable profit growth alongside significant margin volatility. In Q2 FY26, the company reported net sales of ₹192.75 crores, reflecting a quarter-on-quarter increase of 40.51% and a year-on-year growth of 13.32%. This growth trajectory indicates the company's ability to capture market share within the competitive injectables segment. However, the operating margin, while improving to 16.06% from 11.21% in the previous quarter, remains below the 18.34% peak achieved in Q4 FY25, highlighting ongoing challenges in margin consistency.\n\nThe net profit for Q2 FY26 stood at ₹20.13 crores, marking a substantial quarter-on-quarter increase of 109.69% and an impressive year-on-year growth of 473.50%. Despite these positive figures, the pronounced volatility in profitability metrics raises questions about the sustainab..." } ], "total": 339, "sid": "568580", "stock_news_url": "https://www.marketsmojo.com/news/venus-remedies-568580" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "31-Jan-2026", "details": "Copy of newspaper publication of UFR as on 31st December 2025.", "source": "BSE" }, { "caption": "Unaudited Standalone And Consolidated Financial Results As On 31St December 2025", "datetime": "29-Jan-2026", "details": "Unaudited Standalone and Consolidated Financial Results as on 31st December 2025", "source": "BSE" }, { "caption": "Board Meeting Outcome for Outcome Of Board Meeting Dated 29Th January 2026", "datetime": "29-Jan-2026", "details": "Outcome of Board meeting dated 29th January 2026", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Venus Remedies Ltd has declared <strong>30%</strong> dividend, ex-date: 23 Sep 13", "dt": "2013-09-23", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

2 Feb: New 52-week and all-time high at Rs.872.8

3 Feb: Stock hits upper circuit, closes at Rs.799.00 (+1.51%)

6 Feb: Technical momentum shifts amid mixed indicator signals

Week Close: Rs.738.90 (-9.69%) vs Sensex +1.51%

Read full news article

Venus Remedies Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

2026-02-06 08:01:30

Venus Remedies Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish trend. Despite a slight dip in daily price, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, and moving averages that warrant close attention from investors and market analysts alike.

Read full news article

Venus Remedies Ltd Hits Upper Circuit Amid Strong Buying Pressure

2026-02-03 10:05:38

Venus Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 3 Feb 2026, propelled by robust buying interest and a notable intraday price rally. The stock closed at ₹799.0, marking a maximum daily gain of 5%, underscoring renewed investor confidence despite a recent period of consolidation.

Read full news article

Venus Remedies Ltd Hits New 52-Week High at Rs.872.8

2026-02-02 09:48:58

Venus Remedies Ltd has reached a significant milestone by hitting a new 52-week and all-time high of Rs.872.8, marking a remarkable surge in its stock price amid strong market momentum and robust financial performance.

Read full news article

Venus Remedies Ltd Stock Hits Record High of Rs.872.8 on 2 Feb 2026

2026-02-02 09:33:32

Venus Remedies Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a new all-time high of Rs.872.8 on 2 Feb 2026, underscoring its robust performance and sustained growth trajectory in a competitive market environment.

Read full news article

Venus Remedies Ltd Downgraded to Buy Amid Valuation and Technical Shifts

2026-02-02 08:36:53

Venus Remedies Ltd has seen its investment rating downgraded from Strong Buy to Buy as of 1 February 2026, reflecting a recalibration of its valuation and technical outlook despite robust financial performance and quality metrics. The revised Mojo Score now stands at 74.0, signalling a solid but more cautious stance on the stock within the Pharmaceuticals & Biotechnology sector.

Read full news article

Venus Remedies Ltd Valuation Shifts Signal Changing Market Sentiment

2026-02-01 08:02:56

Venus Remedies Ltd has recently experienced a notable shift in its valuation parameters, moving from a very attractive to a fair valuation grade. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, invites a closer examination of the company’s price attractiveness relative to its historical performance and peer group within the Pharmaceuticals & Biotechnology sector.

Read full news article

Venus Remedies Ltd Gains 12.63%: 4 Key Factors Driving the Surge

2026-01-31 17:01:22

Key Events This Week

27 Jan: Stock opens strong at Rs.750.20 (+3.28%)

29 Jan: Q3 FY26 results reveal profit surge; upgraded to Strong Buy; bullish technical momentum

30 Jan: Hits upper circuit at Rs.818.00 (+4.67%) on robust buying

Read full news article

Are Venus Remedies Ltd latest results good or bad?

2026-01-30 19:24:15

Venus Remedies Ltd's latest financial results reveal a complex operational landscape characterized by notable profit growth alongside significant margin volatility. In Q2 FY26, the company reported net sales of ₹192.75 crores, reflecting a quarter-on-quarter increase of 40.51% and a year-on-year growth of 13.32%. This growth trajectory indicates the company's ability to capture market share within the competitive injectables segment. However, the operating margin, while improving to 16.06% from 11.21% in the previous quarter, remains below the 18.34% peak achieved in Q4 FY25, highlighting ongoing challenges in margin consistency. The net profit for Q2 FY26 stood at ₹20.13 crores, marking a substantial quarter-on-quarter increase of 109.69% and an impressive year-on-year growth of 473.50%. Despite these positive figures, the pronounced volatility in profitability metrics raises questions about the sustainab...

Read full news article

View All News